Background Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world...
M. Ting-Lin, E. Antonarakis, X. Wang et al.· medRxiv· 0 citations
Abstract Background Circulating tumor DNA (ctDNA) is an emerging tool for non-invasive disease monitoring in solid tumor oncology, yet its clinical utility in renal cell carcinoma (RCC) remains poorly defined. RCC exhibits variable ctDNA shedding rates, which may limit assay sensitivity particularly in low-burden disea...
Ezra Blumenthal, Paulo Siqueira Do Amaral, Yi Chen et al.· The Oncologist· 0 citations
This analysis compares somatic, germline, immune, transcriptomic, and clinical features of eoRCC vs. typical-onset RCC (toRCC) using a multi-omic real-world dataset and reveals upregulation of hypoxia- and VEGFR-signaling pathways in early-onset ccRCC.
H. Ebrahimi, S. Haake, M. Weitz et al.· The Oncologist· 0 citations
A tissue microarray comprising pRCC tumors and adjacent normal kidney tissue from 102 patients treated at Vanderbilt University Medical Center was assembled andMultivariate machine learning modeling showed that spatial clusters were more strongly predictive of clinical outcomes compared to other feature types.
W. J. Brewer, Joseph A. Vento, Ezra Blumenthal et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
